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Abstract  
Objectives:  To identify the 30 most common adverse drug events or reactions (ADE/ADRs) within the top 200 medications: (1) by raw 
incidence, (2) weighted by prescription volume, (3) and weighted by retail dollars.   
Methods:  The Pharmacy Times Top 200 Medications (as ranked by prescription volume) was utilized to identify the top 200 
medications in 2008.  The ADE/ADRs for each medication were obtained from Facts and Comparisons, Micromedex, and Lexi-Comp 
and entered into a database.  These ADE/ADRs were compiled and summed, identifying the number of times each appeared.  These 
then were ranked to identify the 30 most common ADE/ADRs.  The actual prescription volume and total retail dollars for each 
medication were obtained and listed next to each medication’s ADE/ADR.  The incidence of each ADE/ADR then was weighted by 
actual prescription volume and retail dollars to determine the top 30 most common ADE/ADRs. 
Results:  Initial evaluation resulted in 9829 individual ADE/ADRs and summed into 1477 distinct ADE/ADRs, after adjusting for 
interchangeable terminology.  Examples of the 30 most common ADE/ADRs (raw incidence) included:  dizziness/vertigo, headache, 
nausea, vomiting, and diarrhea/loose stools.  The list remained the same after weighting by actual prescription volume.  After 
weighting by retail dollars, the order of ADE/ADRs changed slightly. 
Conclusion:  Knowledge of ADE/ADRs is important for pharmacists in all healthcare settings.  Consolidating ADE/ADRs for 
medications may enable pharmacists to recall the most common side effects and aid in earlier identification of ADE/ADRs, which may 
positively impact patient safety across practice settings. 
 
 
Introduction 
The role of the community pharmacist and the nature of 
community pharmacy practice have undergone considerable 
evolution in recent decades as the number of medications 
consumed in addition to the spending on prescription drugs 
have markedly increased.  Nearly 81 percent of older adults 
between the ages of 57 and 85 use at least one prescription 
medication and one in three older adults use at least five or 
more prescription medications.
1  Spending on prescription 
drugs has significantly increased from $51 billion in 1993 to 
an estimated $244.8 billion in 2009.  These numbers are 
expected to increase to $453.7 billion by 2018, despite the 
current economic recession.
2  During this same period, the 
level of training and clinical expertise of the pharmacy 
practitioner has increased substantially with the 
implementation of a required Doctor of Pharmacy degree.
3  
From 2000 to 2009, the percentage of licensed pharmacists 
with a Doctor of Pharmacy degree has increased from 
approximately 14 percent to nearly 22 percent.
40  
Pharmacists are well-prepared to identify, address and Original Research  SCIENCE 
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resolve drug-related problems their patients may be 
experiencing and can provide patients with important 
information about adverse drug reactions and adverse drug 
events.
4  
 
An adverse drug reaction (ADR) is typically defined as “harm 
directly caused by a drug at normal doses,”
5 while an adverse 
drug event (ADE) is “harm caused by the use of a drug.”
5  An 
example of an ADR could be myopathy from the usage of a 
statin, while an example of an ADE could be hepatic failure 
from inappropriate overdosing of an opioid combination 
product.  Together, ADEs and ADRs are estimated to result in 
more than 100,000 deaths each year, are between the fourth 
and sixth leading cause of death in the United States, and are 
estimated to account for nearly 10 percent of all hospital 
admissions.
6, 7  The cost of drug-related morbidity and 
mortality creates a significant economic burden, with the cost 
in the United States health care system estimated to exceed 
$177 billion each year.
8  ADE/ADRs are reported to be 
common in the ambulatory population, with many instances 
resulting in hospitalization.
6,7,9  Serious and fatal ADEs 
reported to the U.S. Food and Drug Administration (FDA) 
more than doubled from 1998 to 2005;
7 however, ADE/ADRs 
are underreported.
10-12  According to a systematic review, 
incidence of ADE/ADRs are estimated to be 94 percent higher 
than actually reported.
11  Many of the ADE/ADRs reported 
tend to be considered serious and/or life-threatening.
7  There 
is little information available regarding the prevalence and 
incidence of “tolerable” ADE/ADRs that may reduce patients’ 
quality of life and decrease medication adherence but do not 
reach a minimum threshold of “reportability.” 
 
Previous research has demonstrated pharmacists’ ability to 
reduce ADEs, primarily in the institutional setting.  In one 
study including pharmacists on a pediatric rounds team, 94 
percent of ADEs were prevented.
13  Similar results in other 
studies have substantiated the value of pharmacists in 
reducing ADEs, mainly in the inpatient setting.
14-22  In a study 
by Thomsen and colleagues (2007), medication errors 
resulting in preventable ADEs occur in the prescribing and 
monitoring stage of the medication use process.
23  These 
studies clearly demonstrate that pharmacists have the 
capability to effectively influence the incidence of ADE/ADRs.  
To date, however, the reduction of ADE/ADRs has primarily 
been accomplished in closely-monitored and controlled 
patient populations in institutional settings.
4,14-22  While this 
type of patient care is an extremely vital component of the 
health care system, there is substantial unmet need to 
monitor patients in the ambulatory population for the 
existence of ongoing ADE/ADRs.
20   
 
Community pharmacy practice differs substantially from 
practice in institutional settings, where pharmacists can 
provide feedback through chart reviews and patient 
rounds.
4,14-22  Community pharmacists are more likely to 
contend with the consequences of medication therapy and 
often have less influence on medication therapy choices.  
However, community pharmacists, by virtue of their training 
and accessibility, are uniquely positioned in the health care 
system to address the issue of ongoing ADE/ADRs in 
ambulatory patients.  Indeed, community pharmacist 
counseling interventions have been found to improve 
outcomes by decreasing ADEs in cardiovascular patients.
20  
The Institute for Safe Medication Practices (ISMP) agrees, 
believing that pharmacist counseling improves medication 
use in the ambulatory population and bridges the 
communication gap between healthcare providers and 
patients.
38 
 
 
Community pharmacists often have difficulty engaging in 
lengthy patient communication activities due to the time 
constraints of modern practice.  Approximately 72 percent of 
community pharmacist time is spent in medication dispensing 
activities and managerial duties, allotting less time for patient 
counseling activities.
39  As a result, during a patient 
counseling session, the community pharmacist must discover 
ADE/ADRs a patient is experiencing as rapidly as possible and 
determine which medication is responsible.  While 
knowledge of ADE/ADRs is essential for pharmacists in all 
settings, recollection of every potential ADE/ADR for each 
medication under such circumstances may prove daunting.  
 
The current method of classifying, learning, and recalling 
ADE/ADRs is based on structuring medication knowledge 
within each particular therapeutic class.  This method of 
organizing medication knowledge by pharmacological or 
therapeutic classification provides an efficient approach to 
the prescribing process, since the ADE/ADRs can be analyzed 
prospectively.  Pharmacists can effectively use their 
knowledge to aid in the prospective evaluation process of 
proposed prescribing using this framework.
14-22  However, in 
the community setting, pharmacists typically deal with 
prescriptions retrospectively; when problems occur (i.e. are 
presented with an ADE/ADR), they must work backward to 
determine which medication from the patient’s regimen is 
responsible.  The manner by which drug information has 
traditionally been organized and taught can make this 
process cumbersome when done retrospectively. 
 
Rather than using the current approach, which relies on recall 
of all possible ADE/ADRs for each medication, the 
development of a classification system based on ADE/ADRs 
would provide a list of potential “suspect” medications to the Original Research  SCIENCE 
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pharmacist allowing for more efficient identification of the 
causal agent and enable them to effectively recall the most 
frequently occurring side effects, improving patient safety 
and outcomes. 
 
Objective 
The objectives of this study were to identify the 30 most 
common adverse drug events or reactions (ADE/ADRs) within 
the top 200 medications: (1) by  raw incidence, (2) weighted 
by prescription volume, (3) and weighted by retail dollars. 
 
Methods 
The Pharmacy Times Top 200 Drugs of 2008 list was used to 
identify the prescription medications most commonly used 
within the ambulatory population during 2008.  The 
Pharmacy Times listing ordinally ranks the top 200 
medications according to prescription volume, combining 
both brand and generic medications into a single ranked list, 
using data from IMS Health.
24  There are other publicly-
available lists compiled by Drug Topics (using data from 
SDI/Verispan), but these contain two separate top 200 drug 
lists, one for brand-name medications and another for 
generic medications.
25, 26  
 
Once the Pharmacy Times list was obtained, a database using 
Microsoft Excel
® was created by entering the top 200 
medications.  The medications then were categorized and 
sorted according to pharmacologic class.  Pharmacologic class 
determinations were made using the most recent version of 
Drug Facts and Comparisons (July 2009).  After the top 200 
medications were sorted into pharmacologic classes within 
the database, the adverse drug experiences and adverse drug 
reactions (ADE/ADRs) for each medication were obtained 
from July 2009 to September 2009 from drug information 
resources (Drug Facts and Comparisons, Lexi-Comp, and 
Micromedex) and listed next to each medication in the 
database.  These drug information resources were used to 
create an exhaustive list of all the ADR/ADEs for the top 200 
prescription medications.  Estimates of frequency of 
ADE/ADR occurrence and frequency vs. placebo, when 
available, also were obtained and entered into the database. 
 
After the list of ADE/ADRs was compiled and entered into the 
database for each medication, another list of ADE/ADRs was 
compiled for each pharmacological class.  Common 
ADE/ADRs which occurred for each medication within the 
pharmacologic class were identified and sorted within the 
database.  After entry, the resulting ADE/ADR database for a 
specific pharmacologic class included ADE/ADRs common to 
all medications of the pharmacologic class as well as those 
specific to individual medications.  
 
When the ADE/ADR lists for all identified pharmacologic 
classes were completed, a master list of all ADE/ADRs found 
within the top 200 medications was created and sorted 
according to specific ADE/ADRs.  The resulting master list of 
ADE/ADRs then was analyzed to identify any terms that could 
be considered interchangeable, in order to consolidate the 
list and retain only unique ADE/ADRs.  Terms that were 
identified as interchangeable were verified through a primary 
literature review in Medline, which indicated that the terms 
were used interchangeably in the literature.  Pharmacist 
clinical judgment (by authors Kiersma and Chen) also was 
used, and there were no disagreements regarding the list of 
interchangeable terms.  If, according to the literature and 
clinical judgment, two terms were considered 
interchangeable then the ADE/ADRs were combined.  For 
example, one such interchangeable set of ADE/ADRs 
identified was dyspnea and shortness of breath.  A list of 
similar terms that were consolidated can be found in Table 1.   
 
After the final list was completed, the number of instances in 
which each ADE/ADR occurred within the top 200 
medications was tabulated to rank the most common 
ADE/ADRs.  The final list of ADE/ADRs was weighted by the 
prescription volume for each drug using the prescription drug 
volumes contained in the Drug Topics Top 200 drugs of 2008 
list.
25, 26  The prescription drug volume list was sorted and 
ranked to determine the most common ADE/ADRs weighted 
by prescription volume.  The same method also was used to 
generate the list weighted by retail dollars, using the values 
contained in the Drug Topics list.
36,37  Weighting by 
prescription volume or retail dollars corrects for the 
difference in relative magnitude between all 200 
medications, since the original top 200 list provides only the 
rank of each medication.  For example, information regarding 
the magnitude between the medications at the twenty-fourth 
and twenty-fifth  positions as opposed to the twenty-sixth 
and twenty-seventh positions.   
 
Although the Pharmacy Times Top 200 of 2008 list was used 
to identify the prescription medications,
24 it was necessary to 
utilize the Drug Topics Top 200 of 2008 drug list to generate 
the actual prescription volume and retail dollars for individual 
agents as complete information for all 200 medications was 
unavailable in the Pharmacy Times list .
24-26, 35, 36 The Drug 
Topics Top 200 drug list did not include a prescription volume 
or retail dollars for amlodipine,
25,35  which was listed in the 
Drug Topics top 200 list.  However the Pharmacy Times Top 
200 drug list did provided a prescription volume for 
amlodipine.
24  The ADE/ADRs associated with amlodipine 
were not weighted by retail dollars, as the information was 
unavailable. 
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Results 
Evaluation of the master list of all ADE/ADRs contained within 
the top 200 prescription medications resulted in the 
identification of 9,829 ADE/ADRs.  After consolidation of 
interchangeable terms, 1,477 unique ADE/ADRs remained.   
 
The top five ADE/ADRs (prior to weighting by retail dollars 
and prescription volume) occurring in top 200 drugs were: 1) 
nausea, 2) dizziness/vertigo, 3) headache, 4) vomiting, and 5) 
rash/skin eruption.  The top five most common ADE/ADRs 
weighted by prescription volume were: 1) dizziness/vertigo, 
2) headache, 3) nausea, 4) diarrhea/loose stools, and 5) 
vomiting,  After weighting ADE/ADRs by retail dollars, the top 
five ADE/ADRs were:  1) dizziness/vertigo, 2) fatigue, 3) 
vomiting, 4) nausea, and 5) headache.   
 
Overall, the top 30 unweighted and weighted ADE/ADR lists 
were similar, but there were some differences (see Table 2).  
Results for the top 30 unweighted and weighted by retail 
dollars ADE/ADR lists included angioedema, fever, and 
anaphylaxis, but were not reported in the top 30 list weighted 
by prescription volume.  The unweighted list also did not 
include the ADE/ADRs of angina/chest pain, xerostomia/dry 
mouth, and taste perversion/dysguesia which were included 
on lists weighted by retail dollars and prescription volume.  
Table 2 presents the results of the top 30 ADE/ADRs 
unweighted, weighted by prescription volume, and weighted 
by retail dollars.   Also, the 30 most common ADE/ADRs 
weighted by prescription volume were similar for the 
tabulations including and excluding amlodipine, with only the 
ranking of ADE/ADRs differing.   
 
Discussion 
The intention of this study was to provide preliminary data 
for the future development of an alternative method that 
would provide more information regarding the prevalence 
and aid in identification of unintended consequences 
(ADE/ADRs) associated with medication utilization.  In 2008, 
approximately 2,329,957 top 200 prescription medications 
were dispensed.
25,26  This research project provided 
information on the frequency of the most common ADE/ADRs 
patients are most likely to experience when taking one of the 
top 200 medications, allowing for an estimate of the actual 
incidence of the ADE/ADRs in the ambulatory population 
based on the published literature.   
 
There are several alternate methods whereby this study 
could have been structured.  For example, other publications 
listing the top 200 medications could have been chosen.  
However, there are few other reliable listings of top 200 
medications are publicly-available, and The Pharmacy Times 
and the Drug Topics lists are comprehensive, publicly-
available, and utilize data generated by reliable sources, i.e. 
IMS Health and SDI/Verispan.
24-26    The Pharmacy Times list 
was selected to generate the top 200, since it was used more 
frequently in the literature
27-31 and combined both brand and 
generic medications. 
 
Also, medications were organized according to pharmacologic 
category or class in view of the fact that both practice and the 
literature routinely utilize this method of classification to 
compartmentalize similar medications within 
pharmacological class that tend to share similar therapeutic 
use and ADE/ADRs.  Facts and Comparisons was selected for 
classification purposes due to its utilization in other studies as 
a source of accurate and reliable information.
32, 33  This study 
employed a unique approach to ADE/ADR classification by 
categorizing the top 200 prescription medications by 
ADE/ADR.  To develop an initial list of all possible ADE/ADRs 
experienced within the top 200 medications, three different 
reference software programs (Facts and Comparisons, Lexi-
Comp, and Micromedex) were employed for identification of 
ADE/ADRs due to their demonstrated ability to provide 
comprehensive and accurate information.
32-35  
 
Information regarding the incidence, prevalence, and 
frequencies of ADE/ADRs for individual medications and 
placebo was gathered and entered into the database, when 
available.  However, for a number of medications, ADE/ADR 
incidence and prevalence data was not readily available.  
Many of those medications for which information was not 
available included those which have been on the market for a 
lengthy period of time (e.g., prednisone and amitriptyline).  
Similarly, information regarding the medication versus 
placebo ADE/ADR incidence was frequently unavailable.  
Therefore, our estimates of the most common 30 ADE/ADRs 
could not be adjusted for actual incidence (e.g. 10 percent 
incidence of placebo-induced nausea versus 50 percent 
incidence of medication-induced nausea) due to limitations of 
the data sources.  Further research is needed to determine 
the actual prevalence of ADE/ADRs for many of these 
medications in the ambulatory population.   
 
One problem that arose was clinically similar ADE/ADRs with 
slight differences in terminology. Several ADE/ADRs were 
grouped (as seen in Table 1) using both a primary literature 
review and pharmacist clinical judgment due to differences in 
terminology used in the drug information databases.  
Grouping decisions were determined on the basis of scientific 
knowledge regarding medications provided by literature and 
the pharmacists’ educational background.   In future research 
other ADE/ADRs groupings could be determined, since many 
terms describe ADE/ADRs in different ways.  However, for 
purposes of this study, the research team elected to allow the Original Research  SCIENCE 
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separation of ADE/ADRs unless the definitions were entirely 
interchangeable according to the primary literature and 
clinical judgment.   
 
In this study, the number of occurrences of ADE/ADRs was 
weighted by retail dollars and by prescription volume and 
compared.  The Drug Topics listing of the top 200 medications 
does contain complete information by retail dollars and 
prescription volume for both brand and generic name.
25,26,36, 
37  Both listings were selected, analyzed, and presented to 
avoid systematic bias based on cost differences between 
prescription medications, which could occur if the rankings 
were based solely on retail dollars.  In addition, comparison 
of the list of ADE/ADRs created using both prescription 
volume and retail dollars top 200 rankings provided a method 
for assessing the sensitivity of our methods in creating the 
ADE/ADR lists.  Arguably, our approach to constructing a list 
of the most common ADE/ADRs should be sufficiently 
“sensitive” to be able to discern the differences in ADE/ADR 
incidence in lists generated according to the criteria of 
prescription volume and of dollar volume, which each of our 
lists changed according to the different criteria.  We consider 
the difference in ADE/ADR incidence according to 
prescription volume and retail dollars as evidence for the 
validity of our method of developing the ADE/ADR list. 
 
Limitations 
There were some limitations to this project.  There was 
limited publicly-available information regarding which 
medications comprise the top 200 list.  The Pharmacy Times 
list,
24 while widely-utilized and reliable, does not contain the 
prescription volume for all 200 medications.  It also does not 
contain information regarding the retail dollars for the top 
200 medications.
24  Due to this fact, the Drug Topics list had 
to be used to generate the prescription volume
25,26 and retail 
dollars
35,36 for the top 200 prescription medications.  
Additionally, the Drug Topics list
25,26, 35, 36 does not include 
amlodipine, which is present in the top 200 medications 
reported in The Pharmacy Times list.
24  No information was 
available regarding this omission.  These limitations have 
been acknowledged and accounted for throughout the 
project using conservative methods of analysis and reporting 
of results.  
 
Conclusion 
Pharmacists are well-prepared to identify, address and 
resolve pharmaceutical therapy-related problems their 
patients may be experiencing while providing patients with 
important information about adverse drug reactions.  
Unfortunately due to time constraints, today’s highly trained 
pharmacy practitioner often has difficulty engaging in lengthy 
patient communication activities that are of vital importance 
to a patient’s well-being due to medication dispensing 
functions and managerial activities that take up over 70 
percent of their time daily.
39  Given the limited amount of 
time remaining for patient counseling, the exchange of 
information and problem discovery that occurs during the 
pharmacist-patient interactions needs to be as efficient as 
possible.  Consolidating the ADE/ADRs for the top 200 
medications, each drug class, and eventually all medications 
may enable pharmacists to recall the most common side 
effects and aid in earlier identification of ADE/ADRs a patient 
may be experiencing, which may positively impact patient 
safety across healthcare settings.    When comparing an 
ADE/ADR to a patient’s medication list, organizing 
medications by ADE/ADR also may aid in efficiently 
identifying the causal medication for a reported ADE/ADR.  
Again, while organizing medications according to 
pharmacological class is useful to identify potential ADE/ADRs 
during prospective drug evaluation, it may not be the best 
method for identification of ADE/ADRs in the community 
pharmacy setting.  
 
Pharmacist medication review and counseling have reduced 
the rate of ADEs, thereby improving patient outcomes, 
primarily within the inpatient setting.
14-22  In addition, 
increased identification of ADE/ADRs and subsequent 
counseling in the community setting may lead to greater 
reporting of pertinent ADE/ADRs to the FDA database, which 
can lead to changes in both practice and regulation that 
improve patient safety.
10  This project has derived the 
approximate estimates of the incidence of ADE/ADRs in the 
ambulatory population based on published literature.  We 
have used the database to estimate that given the 
opportunity to ask a patient 30 questions related to the 30 
most common ADE/ADRs, without any prior knowledge 
regarding the specific medications the patient is using, we 
would be able to identify nearly 30 percent of ADE/ADRs.  
Future research can utilize these lists to create instruments 
for the top 200 medications that better estimate the true 
prevalence of ADE/ADRs in the ambulatory patient 
population, and ultimately, develop tools to improve patient 
medication safety. 
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Table 1. Similar Terms Combined Using Clinical Judgment 
 
 
Dyspnea  Shortness of breath 
Rash  Skin eruption 
Dizziness  Vertigo 
Dyspepsia  Indigestion 
Diarrhea  Loose stools 
Arthralgia  Joint pain 
Myalgia  Muscle pain 
Diplopia  Double vision 
Ecchymyosis  Bruising 
Cholelithiasis  Gallstones 
Tremor  Shaking 
Tinnitus  Ringing in ears 
Dysgeusia  Taste disturbances 
Pruritus  Itching 
Urticaria  Hives 
Angina  Chest pain 
Xerostomia  Dry mouth 
 
 Original Research  SCIENCE 
 
http://z.umn.edu/INNOVATIONS                              2011, Vol. 2, No. 1, Article 36                   INNOVATIONS in pharmacy    9 
 
 
 
Table 2. Top 30 Adverse Drug Experiences/Adverse Drug Reactions (ADE/ADRs) in the Top 200 Drugs Unweighted, 
Weighted by Retail Dollars, and Weighted by Prescription (Rx) Volume 
 
ADE/ADRs Unweighted  ADE/ADRs Weighted by Retail Dollars  ADE/ADRs Weighted by Rx Volume 
1.  Nausea  1.  Dizziness/vertigo  1.  Dizziness/vertigo 
2.  Dizziness/Vertigo  2.  Fatigue  2.  Headache   
3.  Headache  3.  Vomiting   3.  Nausea  
4.  Vomiting  4.  Nausea   4.  Vomiting  
5.  Rash/skin eruption  5.  Headache  5.  Diarrhea/loose stools 
6.  Diarrhea/loose stools  6.  Rash/skin eruption  6.  Rash/skin eruption 
7.  Constipation   7.  Angina/chest pain  7.  Constipation  
8.  Insomnia  8.  Insomnia  8.  Angina/chest pain 
9.  Abdominal pain  9.  Diarrhea/loose stools  9.  Fatigue 
10.  Dyspepsia/indigestion  10.  Constipation  10.  Insomnia 
11.  Pruritis/itching  11.  Dyspepsia/indigestion  11.  Abdominal pain 
12.  Fatigue  12.  Abdominal pain  12.  Thrombocytopenia 
13.  Urticaria/hives  13.  Pruritus/itching  13.  Dyspepsia/indigestion 
14.  Allergic reactions  14.  Anaphylaxis  14.  Pruritus/itching 
15.  Depression  15.  Somnolence  15.  Somnolence 
16.  Anaphylaxis  16.  Xerostomia/dry mouth  16.  Allergic reactions  
17.  Dyspnea/shortness of breath  17.  Urticaria/hives  17.  Dyspnea/shortness of breath 
18.  Tremor  18.  Dyspnea/shortness of breath  18.  Hypotension 
19.  Somnolence  19.  Paresthesia  19.  Xerostomia/dry mouth 
20.  Thrombocytopenia  20.  Arthralgia/joint pain   20.  Urticaria/hives 
21.  Arthralgia/joint pain  21.  Depression  21.  Depression 
22.  Palpitations  22.  Tremors  22.  Paresthesia  
23.  Paresthesia  23.  Angioedema  23.  Palpitations 
24.  Anxiety  24.  Thrombocytopenia  24.  Anorexia  
25.  Myalgia/muscle pain  25.  Palpitations  25.  Myalgia/muscle pain 
26.  Hypotension  26.  Anxiety   26.  Anxiety  
27.  Nervousness  27.  Myalgia/muscle pain  27.  Arthralgia/joint pain 
28.  Anorexia  28.  Taste perversion/dysgeusia  28.  Tremors 
29.  Fever  29.  Cough  29.  Taste perversion/dysgeusia 
30.  Angioedema  30.  Fever  30.  Nervousness 
 